Related references
Note: Only part of the references are listed.Complement in malaria immunity and vaccines
Liriye Kurtovic et al.
IMMUNOLOGICAL REVIEWS (2020)
Clinical applications of nanomedicine in cancer therapy
Mohammad Norouzi et al.
DRUG DISCOVERY TODAY (2020)
Nanoconfinement-mediated cancer theranostics
Changsun Kang et al.
ARCHIVES OF PHARMACAL RESEARCH (2020)
Therapeutic Targeting of Vasculature in the Premetastatic and Metastatic Niches Reduces Lung Metastasis
Shanawaz M. Ghouse et al.
JOURNAL OF IMMUNOLOGY (2020)
Overcoming Nanoparticle-Mediated Complement Activation by Surface PEG Pairing
Martina Pannuzzo et al.
NANO LETTERS (2020)
Complement as Prognostic Biomarker and Potential Therapeutic Target in Renal Cell Carcinoma
Britney Reese et al.
JOURNAL OF IMMUNOLOGY (2020)
Enhancing cancer immunotherapy with nanomedicine
Darrell J. Irvine et al.
NATURE REVIEWS IMMUNOLOGY (2020)
The Interplay Between Blood Proteins, Complement, and Macrophages on Nanomedicine Performance and Responses
S. Moein Moghimi et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2019)
Tumor Cells Hijack Macrophage-Produced Complement C1q to Promote Tumor Growth
Lubka T. Roumenina et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Thirty Years of Cancer Nanomedicine: Success, Frustration, and Hope
Lucia Salvioni et al.
CANCERS (2019)
Targeting Integrins in Cancer Nanomedicine: Applications in Cancer Diagnosis and Therapy
Ping-Hsiu Wu et al.
CANCERS (2019)
Curvature-dependent effects of nanotopography on classical immune complement activation
Emma Westas Janco et al.
ACTA BIOMATERIALIA (2018)
Liposome-induced immunosuppression and tumor growth is mediated by macrophages and mitigated by liposome-encapsulated alendronate.
Robin Rajan et al.
JOURNAL OF CONTROLLED RELEASE (2018)
Targeting complement-mediated immunoregulation for cancer immunotherapy
Martin Kolev et al.
SEMINARS IN IMMUNOLOGY (2018)
Human Properdin Opsonizes Nanoparticles and Triggers a Potent Pro-inflammatory Response by Macrophages without Involving Complement Activation
Lubna Kouser et al.
FRONTIERS IN IMMUNOLOGY (2018)
Complement C3 Plays a Key Role in Inducing Humoral and Cellular Immune Responses to Influenza Virus Strain-Specific Hemagglutinin-Based or Cross-Protective M2 Extracellular Domain-Based Vaccination
Yu-Jin Kim et al.
JOURNAL OF VIROLOGY (2018)
Involvement of complement activation in the pulmonary vasoactivity of polystyrene nanoparticles in pigs: unique surface properties underlying alternative pathway activation and instant opsonization
Tamas Meszaros et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2018)
Complement in cancer: untangling an intricate relationship
Edimara S. Reis et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo
Fangfang Chen et al.
NATURE NANOTECHNOLOGY (2017)
The Ribosomal Protein S19 Suppresses Antitumor Immune Responses via the Complement C5a Receptor 1
Maciej M. Markiewski et al.
JOURNAL OF IMMUNOLOGY (2017)
Polyplex Evolution: Understanding Biology, Optimizing Performance
Arnaldur Hall et al.
MOLECULAR THERAPY (2017)
Non-specific adsorption of complement proteins affects complement activation pathways of gold nanomaterials
Quang Huy Quach et al.
NANOTOXICOLOGY (2017)
Bypassing adverse injection reactions to nanoparticles through shape modification and attachment to erythrocytes
Peter Popp Wibroe et al.
NATURE NANOTECHNOLOGY (2017)
Formation of the Protein Corona: The Interface between Nanoparticles and the Immune System
Francesco Barbero et al.
SEMINARS IN IMMUNOLOGY (2017)
Nanoparticle interactions with the immune system: clinical implications for Liposome-Based cancer chemotherapy
Ninh M. La-Beck et al.
FRONTIERS IN IMMUNOLOGY (2017)
Mechanisms and Barriers in Cancer Nanomedicine: Adressing Challenges, Looking for Solutions
Thomas J. Anchordoquy et al.
ACS NANO (2017)
New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy
Alberto A. Gabizon et al.
DRUG RESISTANCE UPDATES (2016)
Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin
Grant H. Petersen et al.
JOURNAL OF CONTROLLED RELEASE (2016)
The impact of nanoparticle protein corona on cytotoxicity, immunotoxicity and target drug delivery
Claudia Corbo et al.
NANOMEDICINE (2016)
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
Daniel Bobo et al.
PHARMACEUTICAL RESEARCH (2016)
Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies
Ronald P. Taylor et al.
SEMINARS IN IMMUNOLOGY (2016)
C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation
Roberta Bulla et al.
NATURE COMMUNICATIONS (2016)
Autocrine Complement Inhibits IL10-Dependent T-cell-Mediated Antitumor Immunity to Promote Tumor Progression
Yu Wang et al.
CANCER DISCOVERY (2016)
Materials design at the interface of nanoparticles and innate immunity
Gregory L. Szeto et al.
JOURNAL OF MATERIALS CHEMISTRY B (2016)
Activation of Human Complement System by Dextran-Coated Iron Oxide Nanoparticles Is Not Affected by Dextran/Fe Ratio, Hydroxyl Modifications, and Crosslinking
Guankui Wang et al.
FRONTIERS IN IMMUNOLOGY (2016)
The return of the prodigal son and the extraordinary development route of antibody TGN1412-lessons for drug development and clinical pharmacology
Marcel J. H. Kenter et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
PTX3 Is an Extrinsic Oncosuppressor Regulating Complement-Dependent Inflammation in Cancer
Eduardo Bonavita et al.
CELL (2015)
Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials - Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm
S. Vessillier et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2015)
Monitoring and Cell-Specific Deletion of C5aR1 Using a Novel Floxed GFP-C5aR1 Reporter Knock-in Mouse
Christian M. Karsten et al.
JOURNAL OF IMMUNOLOGY (2015)
Pulmonary Alveolar Macrophages Contribute to the Premetastatic Niche by Suppressing Antitumor T Cell Responses in the Lungs
Sharad K. Sharma et al.
JOURNAL OF IMMUNOLOGY (2015)
Liposome promotion of tumor growth is associated with angiogenesis and inhibition of antitumor immune responses
Manoj K. Sabnani et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2015)
Liposome-protein corona in a physiological environment: Challenges and opportunities for targeted delivery of nanomedicines
Giulio Caracciolo
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2015)
Experimental drug that injured UK volunteers resumes in human trials
Owen Dyer
BMJ-BRITISH MEDICAL JOURNAL (2015)
Experimental drug that injured UK volunteers resumes in human trials
Owen Dyer
BMJ-BRITISH MEDICAL JOURNAL (2015)
Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients
Talia Golan et al.
CANCER MEDICINE (2015)
Mediation of a non-proteolytic activation of complement component C3 by phospholipid vesicles
Yvonne Klapper et al.
BIOMATERIALS (2014)
Complement C5a Receptor Facilitates Cancer Metastasis by Altering T-Cell Responses in the Metastatic Niche
Surya Kumari Vadrevu et al.
CANCER RESEARCH (2014)
Cytokine release assays: Current practices and future directions
D. Finco et al.
CYTOKINE (2014)
Cancer nanomedicine and the complement system activation paradigm: Anaphylaxis and tumour growth
S. M. Moghimi
JOURNAL OF CONTROLLED RELEASE (2014)
Complement activation-related pseudoallergy: A stress reaction in blood triggered by nanomedicines and biologicals
Janos Szebeni
MOLECULAR IMMUNOLOGY (2014)
Just so stories: The random acts of anti-cancer nanomedicine performance
Seyed Moein Moghimi et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2014)
Autocrine Effects of Tumor-Derived Complement
Min Soon Cho et al.
CELL REPORTS (2014)
The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo
Hiroshi Maeda et al.
ADVANCED DRUG DELIVERY REVIEWS (2013)
Liposomal drug delivery systems: From concept to clinical applications
Theresa M. Allen et al.
ADVANCED DRUG DELIVERY REVIEWS (2013)
Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release
David Eastwood et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Giving monoclonal antibodies to healthy volunteers in phase 1 trials: is it safe?
Elizabeth Tranter et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Nanoparticle clearance is governed by Th1/Th2 immunity and strain background
Stephen W. Jones et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Complement monitoring of Pluronic 127 gel and micelles: Suppression of copolymer-mediated complement activation by elevated serum levels of HDL, LDL, and apolipoproteins AI and B-100
Islam Hamad et al.
JOURNAL OF CONTROLLED RELEASE (2013)
Complement in Immune and Inflammatory Disorders: Pathophysiological Mechanisms
Daniel Ricklin et al.
JOURNAL OF IMMUNOLOGY (2013)
The Role of Pegylated Liposomal Doxorubicin in Ovarian Cancer: A Meta-Analysis of Randomized Clinical Trials
Jean-Marie Gibson et al.
ONCOLOGIST (2013)
Translational Studies of Phenotypic Probes for the Mononuclear Phagocyte System and Liposomal Pharmacology
Whitney P. Caron et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2013)
History of myeloid-derived suppressor cells
James E. Talmadge et al.
NATURE REVIEWS CANCER (2013)
Regulation of Humoral Immunity by Complement
Michael C. Carroll et al.
IMMUNITY (2012)
Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress
Twan Lammers et al.
JOURNAL OF CONTROLLED RELEASE (2012)
Anaphylatoxin C5a Creates a Favorable Microenvironment for Lung Cancer Progression
Leticia Corrales et al.
JOURNAL OF IMMUNOLOGY (2012)
Different Effect of Hydrogelation on Antifouling and Circulation Properties of Dextran-Iron Oxide Nanoparticles
Priya Prakash Karmali et al.
MOLECULAR PHARMACEUTICS (2012)
Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression
Suzanne Ostrand-Rosenberg et al.
SEMINARS IN CANCER BIOLOGY (2012)
Genetic and Pharmacologic Inhibition of Complement Impairs Endothelial Cell Function and Ablates Ovarian Cancer Neovascularization
Selene Nunez-Cruz et al.
NEOPLASIA (2012)
Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: Prediction and prevention
Janos Szebeni et al.
ADVANCED DRUG DELIVERY REVIEWS (2011)
Material properties in complement activation
S. Moein Moghimi et al.
ADVANCED DRUG DELIVERY REVIEWS (2011)
Engineering complement activation on polypropylene sulfide vaccine nanoparticles
Susan N. Thomas et al.
BIOMATERIALS (2011)
Variable Antibody-dependent Activation of Complement by Functionalized Phospholipid Nanoparticle Surfaces
Christine T. N. Pham et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Nanomedicine(s) under the Microscope
Ruth Duncan et al.
MOLECULAR PHARMACEUTICS (2011)
Distinct Polymer Architecture Mediates Switching of Complement Activation Pathways at the Nanosphere-Serum Interface: Implications for Stealth Nanoparticle Engineering
Islam Hamad et al.
ACS NANO (2010)
Curvature of Synthetic and Natural Surfaces Is an Important Target Feature in Classical Pathway Complement Activation
Martin Bjerregard Pedersen et al.
JOURNAL OF IMMUNOLOGY (2010)
Influence of Polyethyleneglycol Modification on Phagocytic Uptake of Polymeric Nanoparticles Mediated by Immunoglobulin G and Complement Activation
Anshu Yang et al.
JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY (2010)
Immunocompatibility properties of lipid-polymer hybrid nanoparticles with heterogeneous surface functional groups
Carolina Salvador-Morales et al.
BIOMATERIALS (2009)
Differential proteomics analysis of the surface heterogeneity of dextran iron oxide nanoparticles and the implications for their in vivo clearance
Dmitri Simberg et al.
BIOMATERIALS (2009)
Influence of PEG chain on the complement activation suppression and longevity in vivo prolongation of the PCL biomedical nanoparticles
Xiaoqian Shan et al.
BIOMEDICAL MICRODEVICES (2009)
Visualizing B cell capture of cognate antigen from follicular dendritic cells
Kazuhiro Suzuki et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Complement-mediated tumour growth: Implications for cancer nanotechnology and nanomedicines
S. M. Moghimi et al.
MOLECULAR IMMUNOLOGY (2009)
Systematic Surface Engineering of Magnetic Nanoworms for in vivo Tumor Targeting
Ji-Ho Park et al.
SMALL (2009)
Is complement good or bad for cancer patients? A new perspective on an old dilemma
Maciej M. Markiewski et al.
TRENDS IN IMMUNOLOGY (2009)
Magnetic iron oxide nanoworms for tumor targeting and imaging
Ji-Ho Park et al.
ADVANCED MATERIALS (2008)
Electrostatic interactions and complement activation on the surface of phospholipid vesicle containing acidic lipids: Effect of the structure of acidic groups
Keitaro Sou et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2008)
Complement activation on surfaces carrying amino groups
Mitsuaki Toda et al.
BIOMATERIALS (2008)
Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells
Michael G. Strainic et al.
IMMUNITY (2008)
Clinical applications of magnetic nanoparticles for hyperthermia
Burghard Thiesen et al.
INTERNATIONAL JOURNAL OF HYPERTHERMIA (2008)
The alternative complement pathway revisited
Morten Harboe et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2008)
Liposome-mediated triggering of complement cascade
S. Moein Moghimi et al.
JOURNAL OF LIPOSOME RESEARCH (2008)
Effects of covalent functionalization on the biocompatibility characteristics of multi-walled carbon nanotubes
Carolina Salvador-Morales et al.
JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY (2008)
Complement activation by PEGylated single-walled carbon nanotubes is independent of C1q and alternative pathway turnover
Islam Hamad et al.
MOLECULAR IMMUNOLOGY (2008)
Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution
Marina A. Dobrovolskaia et al.
MOLECULAR PHARMACEUTICS (2008)
Modulation of the antitumor immune response by complement
Maciej M. Markiewski et al.
NATURE IMMUNOLOGY (2008)
The role of complement in the success of vaccination with conjugated vs. unconjugated polysaccharide antigen
Nur'ain Salehen et al.
VACCINE (2008)
An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin
Alberto Gabizon et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner
Tatsuhiro Ishida et al.
JOURNAL OF CONTROLLED RELEASE (2007)
Exploiting lymphatic transport and complement activation in nanoparticle vaccines
Sai T. Reddy et al.
NATURE BIOTECHNOLOGY (2007)
Function, structure and therapeutic potential of complement C5a receptors
P. N. Monk et al.
BRITISH JOURNAL OF PHARMACOLOGY (2007)
PEGylation of microspheres for therapeutic embolization: Preparation, characterization and biological performance evaluation
Faten Madani et al.
BIOMATERIALS (2007)
Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes
XinYu Wang et al.
JOURNAL OF CONTROLLED RELEASE (2007)
Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production
S. Moein Moghimi et al.
FASEB JOURNAL (2006)
Structure of C3b reveals conformational changes that underlie complement activity
Bert J. C. Janssen et al.
NATURE (2006)
Evaluation of pegylated lipid nanocapsules versus complement system activation and macrophage uptake
A. Vonarbourg et al.
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A (2006)
Concentration dependent structural ordering of poloxamine 908 on polystyrene nanoparticles and their modulatory role on complement consumption
O. Al-Hanbali et al.
JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY (2006)
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells
E Bettelli et al.
NATURE (2006)
Complement activation and protein adsorption by carbon nanotubes
C Salvador-Morales et al.
MOLECULAR IMMUNOLOGY (2006)
Complement activation-related pseudoallergy: A new class of drug-induced acute immune toxicity
J Szebeni
TOXICOLOGY (2005)
Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions
A Chanan-Khan et al.
ANNALS OF ONCOLOGY (2003)
Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications
H Maeda et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2003)
Progress in human tumour immunology and immunotherapy
SA Rosenberg
NATURE (2001)
The role of complement activation in hypersensitivity to pegylated liposomal doxorubicin (DOXIL (R))
J Szebeni et al.
JOURNAL OF LIPOSOME RESEARCH (2000)
Share Paper
